title: Part II: Checkpoint inhibitors in cancer therapy.
authors.affiliation: University of California, San Francisco, 1600 Divisadero St, San Francisco, CA 94143, USA.
authors.forename: Adil I
authors.initials: AI
authors.lastname: Daud
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000276:immunology; D014408:Biomarkers, Tumor / Q000378:metabolism; D060908:CTLA-4 Antigen / Q000276:immunology; D004359:Drug Therapy, Combination; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000072737:Myeloid-Derived Suppressor Cells / Q000276:immunology*; D009369:Neoplasms / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology; D019009:Proto-Oncogene Proteins c-kit / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D060890:B7-H1 Antigen; D014408:Biomarkers, Tumor; D060908:CTLA-4 Antigen; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D019009:Proto-Oncogene Proteins c-kit